knowledge -WSS

knowledge

author：entertainment 2025-10-01 04:13:18 - browse：61

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Dementia risk linked to living in disadvantaged areas: Study

Wikipedia

focus

WSS

Neutralizing antibodies against HIV shows promise in children

How corporate America is slashing DEI workers amid backlash to diversity programs

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Drinking water from half of US faucets contains PFAS: Study

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

There’s a way to spot data fakery. All journals should be using it

The high cost of giving birth even with insurance

California man arrested in connection with serial murders of Mexican strip club workers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Judge denies Trump's request for new trial in E. Jean Carroll case

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Psychedelics group wrestles with new pharma identity

Caribou posts encouraging results on off

hotspot

Rare Northern Lights show in US this week: Where and how to see it

Neutralizing antibodies against HIV shows promise in children

Extensive review finds private equity owners jack up cost of care

Delta passengers in Vegas fall sick while waiting on flight in triple

FDA approves Leqembi, a milestone in Alzheimer’s treatment

How a Boston hospital is priming medical residents to use GPT

Wikipedia

focus

focus

focus